References
- Shinohara A, Yoshiki Y, Masamoto Y, . Moxifloxacin is more effective in reducing chemotherapy-induced febrile neutropenia with hematological malignancies than tosufloxacin. Leuk Lymphoma 2013;54:794–798.
- Gafter-Gvili A, Fraser A, Paul M, . Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979–995.
- Bucaneve G, Micozzi A, Menichetti F, . Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
- Vehreschild JJ, Moritz G, Vehreschild MJGT, . Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation:a randomised trial. Int J Antimicrob Agents 2012;39:130–134.
- Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: a word of caution. Leuk Lymphoma 2011;52:5–6.
- Segal BH, Freifeld AG, Baden LR, . Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122–174.
- Slavin MA, Lingaratnam S, Mileshkin L, . Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011;41:102–109.
- Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011;24:545–553.
- Ruiz J, Pons MJ, Gomes C. Transferable mechanisms of quinolone resistance. Int J Antimicrob Agents 2012;40:196–203.
- Tam VH, Louie A, Fritsche TR, . Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007; 195:1818–1827.
- Averbuch D, Cordonnier C, Kern W, . 4th European Conference on Infections in Leukaemia - Empirical and targeted antibacterial therapy. 2011. Available from: http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL4%202011%20Bacterial%20resistance%20in%20Haematology.pdf
- Martinez JA, Cobos-Trigueros N, Soriano A, . Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010;54:3590–3596.
- Boucher HW, Talbot GH, Bradley JS, . Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
- Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection 2012;40:239–262.
- Kern WV, Steib-Bauert M, Pritzkow A, . Fluoroquinolone prophylaxis in haematology-oncology patients - is it still useful? Clin Microbiol Infect 2009;15(Suppl.): Abstract 0299.